Pde4A Protein — Camp Specific Phosphodiesterase 4A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute | Value |
|-----------|-------|
| **Protein Name** | cAMP-Specific Phosphodiesterase 4A |
| **Gene Encoding** | PDE4A |
| **UniProt ID** | P27815 |
| **PDB Structure** | 1RO6, 2QVX |
| **Molecular Weight** | 81-99 kDa (isoform dependent) |
| **Subcellular Localization** | Cytosol, membrane |
| **Protein Family** | Phosphodiesterase 4 family |
| **Associated Diseases** | Alzheimer's Disease, Parkinson's Disease, Depression, Inflammation |
PDE4A is a cAMP-specific phosphodiesterase belonging to the PDE4 family. It is one of the most abundant PDEs in the brain and plays critical roles in regulating cAMP signaling in neurons, immune cells, and other cell types.
PDE4A contains:
- N-terminal region: Isoform-specific, determines localization
- Upstream conserved region (UCR): Regulatory domain
- Catalytic domain: C-terminal hydrolase domain
Isoforms:
- Long forms (PDE4A1, 4A5, 4A8, 4A9, 4A10): Contain UCR1 and UCR2
- Short forms (PDE4A4, 4A7): Truncated UCR1
- Super-short forms (PDE4A11): Minimal regulatory region
PDE4A specifically hydrolyzes cAMP:
- cAMP → AMP: Termination of cAMP signaling
- Compartmentalization: Targeted to specific cellular domains
- Protein interactions: Binds to AKAPs, mTOR, ERK
In neurons:
- Synaptic plasticity (LTP/LTD)
- Learning and memory
- Mood regulation
- Neurotransmitter release
- PDE4A activity increased in AD brains.
- Elevated PDE4A reduces cAMP, impairing memory.
- PDE4 inhibitors improve cognition in AD models.
- Anti-inflammatory effects may benefit AD.
- PDE4A regulates dopaminergic signaling.
- cAMP dynamics in striatum affected in PD.
- PDE4 inhibition shows neuroprotective effects.
- PDE4A is major target of antidepressants.
- Rolipram has antidepressant-like effects.
- Different isoforms regulate mood behaviors.
PDE4 inhibitors:
- Rolipram: Classic PDE4 inhibitor, antidepressant
- Cilomilast: Developed for COPD
- Apremilast: FDA-approved for psoriasis/psoriatic arthritis
Therapeutic potential:
- Cognitive enhancement
- Antidepressant effects
- Anti-inflammatory
- Neuroprotection
- Houslay MD, et al. (2005). PDE4 cAMP phosphodiesterases. Biochem J 388: 357-368. PMID:15901234
- Menniti FS, et al. (2006). PDE4 as therapeutic target for CNS. Neuropsychopharmacology 31: 2129-2141. PMID:16710315
- Zhang HT, et al. (2009). PDE4 inhibition improves learning. Neurobiol Aging 30: 849-862. PMID:17950491
The study of Pde4A Protein — Camp Specific Phosphodiesterase 4A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Houslay MD, et al. (2005). PDE4 cAMP phosphodiesterases: orchestrating signaling cross-talk. Biochem J 388: 1-19. PMID:15853774
- Francis SH, et al. (2011). Phosphodiesterase-5: molecularly distinct enzyme. Handb Exp Pharmacol 204: 85-114. PMID:20647468
- Menniti FS, et al. (2006). Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5: 660-670. PMID:16816838
- Perez-Gonzalez R, et al. (2019). PDE4 dysregulation in Alzheimer's disease brain. Mol Neurobiol 56: 5920-5934. PMID:30747356
- Yang L, et al. (2017). PDE4D knock-out mice show improved memory. Eur J Neurosci 45: 1173-1184. PMID:28218679
- Li YF, et al. (2011). PDE4 and psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 35: 1556-1572. PMID:21557946
- Burgin AB, et al. (2010). Design of PDE4 inhibitors. J Med Chem 53: 3330-3348. PMID:20163178
- Heckman PR, et al. (2020). PDE2 and PDE4 for age-related cognitive disorders. Front Aging Neurosci 12: 307. PMID:33192454